Will GoPro Capture the Image?

Steve Kanaval  |

The Honeymoon is Over after Summer's IPO

GoPro, Inc. (GPRO) went public in July at $24 and traded up 100% in the first week of trading, getting lots of media attention.
The cool, user-generated videos with secure ways to attach cameras to helmets, bikes and animals gave the world a unique bird's eye view of what the consumer wanted to do with a camera. I am not kidding about the camera - click here to see a bird's eye view. I think the user generated videos are more important than the camera itself.

Putting the Selfie Before the Horse

I always find technology stocks get a little ahead of themselves when investors own the gadget itself a good example would be Apple, Inc. (AAPL) with iPod, BlackBerry Limited (BBRY) or Xbox, because  investors have equal access and can touch and feel and show it off to their friends - but more important, it becomes an accessory - Apple iPhone's are an accessory for the text generation. This is translated to "WOW! Everyone will buy this!" So shares get on this bandwagon and run to such lofty multiples that it takes an accountant (or CFO) to bring you back to earth and ask "Do you realize how many of these they need to sell to achieve this level?" This is a question investors start asking themselves when the stock gets a pullback. The next being "What were we thinking?" I think GoPro investors are asking these questions.

GoPro will be viewed as one of the original technology investments for a generation, so shorting them is not a smart thing to do. New cameras, a new partner or a viral video from the website will reignite consumer awareness. This can and will move share price.

The concept behind GoPro's business comes in two main parts. First, GoPro has built its brand up as catering to high-end enthusiasts of extreme sports, ranging from snowboarding and backcountry downhill skiing to skydiving and deepwater diving. As social media sources have driven greater demand to be able to share one's experiences with friends, GoPro's first-person perspective has become increasingly attractive to its users. I love my GoPro and always carry it with me for family events or even normal bike rides - I use this camera much more than I use my cell phone camera - but mainly because the harness allows you to be hands free - and in many cases - unnoticed. The camera is great for fisherman, snowmobilers, really any sport enthusiast. As a market observer, I think share prices will be as volatile as watching the camera attached to the front of a surfboard.

In the early days of technology stocks, you had the four horseman: AOL, Inc. (AOL) , Microsoft Corporation (MSFT) , Intel Corporation (INTC) and Oracle Corporation (ORCL) . Twenty years later you have Facebook, Inc. (FB) , Twitter Inc. (TWTR) , Linkedin Corp. (LNKD) and maybe GoPro. In today's world of archiving every move, action or event, the four horseman of today's generation are not about accessing the internet - they are about using it with the latest and greatest new technology!

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Symbol Name Price Change % Volume
ORCL Oracle Corporation 47.94 0.35 0.74 16,480,211 Trade
GPRO GoPro Inc. 6.62 -0.03 -0.45 1,778,698 Trade
FB Facebook Inc. 154.78 0.73 0.47 15,398,288 Trade
INTC Intel Corporation 45.01 1.01 2.30 34,242,277 Trade
AAPL Apple Inc. 220.65 1.34 0.61 28,773,656 Trade
TWTR Twitter Inc. 29.18 0.35 1.21 21,715,061 Trade
LNKD LinkedIn Corporation Class A n/a n/a n/a 0 Trade
BBRY BB BlackBerry Limited
MSFT Microsoft Corporation 109.63 0.97 0.89 26,489,859 Trade


Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.